Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 41 | 2023 | 5686 | 5.350 |
Why?
|
Melanoma | 30 | 2023 | 5510 | 4.450 |
Why?
|
Nevus, Pigmented | 11 | 2023 | 219 | 4.340 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 6 | 2023 | 67 | 3.700 |
Why?
|
Melanosis | 4 | 2023 | 78 | 2.410 |
Why?
|
Dermatology | 12 | 2023 | 872 | 2.180 |
Why?
|
Basal Cell Nevus Syndrome | 2 | 2022 | 40 | 1.550 |
Why?
|
Skin | 12 | 2023 | 4364 | 1.440 |
Why?
|
Granuloma | 3 | 2023 | 319 | 1.020 |
Why?
|
Nevus, Blue | 1 | 2023 | 38 | 0.940 |
Why?
|
Neurocutaneous Syndromes | 2 | 2023 | 51 | 0.920 |
Why?
|
Sentinel Lymph Node Biopsy | 6 | 2023 | 709 | 0.890 |
Why?
|
Callosities | 1 | 2021 | 4 | 0.840 |
Why?
|
DNA, Neoplasm | 2 | 2020 | 1758 | 0.840 |
Why?
|
Sunburn | 2 | 2019 | 155 | 0.800 |
Why?
|
Skin Diseases, Viral | 1 | 2021 | 21 | 0.800 |
Why?
|
Nevus of Ota | 1 | 2021 | 4 | 0.790 |
Why?
|
Pigmentation Disorders | 1 | 2021 | 101 | 0.790 |
Why?
|
Granuloma, Pyogenic | 1 | 2021 | 48 | 0.780 |
Why?
|
Pseudoxanthoma Elasticum | 1 | 2020 | 12 | 0.780 |
Why?
|
Penicillamine | 1 | 2020 | 59 | 0.770 |
Why?
|
Skin Abnormalities | 1 | 2021 | 60 | 0.770 |
Why?
|
Hepatolenticular Degeneration | 1 | 2020 | 69 | 0.750 |
Why?
|
Carcinoma, Basal Cell | 3 | 2020 | 545 | 0.740 |
Why?
|
Nevus | 1 | 2022 | 204 | 0.740 |
Why?
|
Cumulative Trauma Disorders | 1 | 2021 | 147 | 0.730 |
Why?
|
Skin Diseases | 4 | 2021 | 1065 | 0.660 |
Why?
|
Fingers | 1 | 2021 | 513 | 0.650 |
Why?
|
Child | 36 | 2023 | 77709 | 0.640 |
Why?
|
Acne Vulgaris | 1 | 2022 | 302 | 0.630 |
Why?
|
Aluminum Compounds | 1 | 2018 | 51 | 0.630 |
Why?
|
Dermoscopy | 1 | 2018 | 56 | 0.610 |
Why?
|
Hypersensitivity, Delayed | 1 | 2018 | 484 | 0.580 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2022 | 4420 | 0.570 |
Why?
|
Urticaria | 1 | 2018 | 150 | 0.560 |
Why?
|
Cleft Lip | 1 | 2021 | 478 | 0.550 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 612 | 0.540 |
Why?
|
Cleft Palate | 1 | 2021 | 560 | 0.530 |
Why?
|
Drug Eruptions | 3 | 2014 | 297 | 0.530 |
Why?
|
Sweat Gland Diseases | 1 | 2015 | 11 | 0.530 |
Why?
|
Chlorides | 1 | 2018 | 667 | 0.510 |
Why?
|
Eccrine Glands | 1 | 2015 | 45 | 0.510 |
Why?
|
Urinary Bladder | 5 | 2008 | 1172 | 0.480 |
Why?
|
Abnormalities, Multiple | 1 | 2021 | 1416 | 0.470 |
Why?
|
Leg Injuries | 1 | 2015 | 178 | 0.450 |
Why?
|
Biopsy | 7 | 2021 | 6756 | 0.440 |
Why?
|
Hamartoma | 1 | 2015 | 238 | 0.440 |
Why?
|
Giant Cells | 1 | 2013 | 187 | 0.420 |
Why?
|
Central Nervous System Neoplasms | 1 | 2021 | 895 | 0.420 |
Why?
|
Telemedicine | 4 | 2022 | 2872 | 0.420 |
Why?
|
Language | 1 | 2021 | 1471 | 0.410 |
Why?
|
Clobetasol | 2 | 2014 | 34 | 0.400 |
Why?
|
Humans | 77 | 2023 | 744343 | 0.400 |
Why?
|
Anti-Inflammatory Agents | 2 | 2012 | 1790 | 0.390 |
Why?
|
Cyclin D1 | 1 | 2013 | 463 | 0.380 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2014 | 547 | 0.350 |
Why?
|
Pyoderma Gangrenosum | 1 | 2010 | 76 | 0.340 |
Why?
|
Hair Diseases | 1 | 2009 | 74 | 0.330 |
Why?
|
Ultraviolet Rays | 1 | 2014 | 1060 | 0.330 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 300 | 0.330 |
Why?
|
Diagnosis, Differential | 6 | 2023 | 12959 | 0.320 |
Why?
|
Adolescent | 20 | 2023 | 85781 | 0.320 |
Why?
|
Child, Preschool | 15 | 2023 | 41006 | 0.320 |
Why?
|
Pathology, Clinical | 1 | 2012 | 368 | 0.320 |
Why?
|
Exocytosis | 3 | 2008 | 353 | 0.300 |
Why?
|
Infant | 12 | 2023 | 35136 | 0.290 |
Why?
|
Eczema | 2 | 2018 | 231 | 0.270 |
Why?
|
Vaccination | 1 | 2018 | 3278 | 0.260 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 7181 | 0.260 |
Why?
|
Adrenal Cortex Hormones | 2 | 2018 | 1855 | 0.210 |
Why?
|
Retrospective Studies | 14 | 2023 | 77449 | 0.200 |
Why?
|
Trientine | 1 | 2020 | 11 | 0.200 |
Why?
|
Dermatitis, Atopic | 2 | 2019 | 654 | 0.190 |
Why?
|
Scalp | 1 | 2023 | 380 | 0.190 |
Why?
|
Pamphlets | 1 | 2020 | 75 | 0.190 |
Why?
|
Melanins | 1 | 2022 | 289 | 0.180 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2021 | 140 | 0.180 |
Why?
|
Glucocorticoids | 2 | 2021 | 2107 | 0.180 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4560 | 0.180 |
Why?
|
Genomics | 2 | 2022 | 5720 | 0.180 |
Why?
|
Aminoquinolines | 1 | 2020 | 109 | 0.180 |
Why?
|
Female | 29 | 2023 | 380194 | 0.180 |
Why?
|
Lip | 1 | 2021 | 195 | 0.180 |
Why?
|
Immunologic Factors | 2 | 2022 | 1580 | 0.170 |
Why?
|
Young Adult | 9 | 2021 | 56430 | 0.170 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2020 | 4034 | 0.160 |
Why?
|
Communication Barriers | 1 | 2021 | 398 | 0.160 |
Why?
|
Patch Tests | 1 | 2018 | 53 | 0.150 |
Why?
|
Ambulatory Care Facilities | 2 | 2021 | 933 | 0.150 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2008 | 179 | 0.150 |
Why?
|
Sunlight | 1 | 2019 | 325 | 0.150 |
Why?
|
Histamine Antagonists | 1 | 2018 | 93 | 0.150 |
Why?
|
Remote Consultation | 1 | 2020 | 238 | 0.150 |
Why?
|
Male | 24 | 2022 | 350118 | 0.150 |
Why?
|
Urination | 1 | 2008 | 204 | 0.150 |
Why?
|
rab GTP-Binding Proteins | 1 | 2008 | 246 | 0.140 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6234 | 0.140 |
Why?
|
Comparative Genomic Hybridization | 1 | 2018 | 496 | 0.140 |
Why?
|
Antibodies, Monoclonal | 2 | 2012 | 9274 | 0.140 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2019 | 5442 | 0.140 |
Why?
|
Adult | 12 | 2023 | 214055 | 0.130 |
Why?
|
Health Services Accessibility | 3 | 2022 | 5137 | 0.130 |
Why?
|
Acneiform Eruptions | 1 | 2014 | 4 | 0.130 |
Why?
|
Dermatitis, Phototoxic | 1 | 2014 | 15 | 0.130 |
Why?
|
Parents | 2 | 2019 | 3407 | 0.130 |
Why?
|
Fluorouracil | 1 | 2020 | 1619 | 0.130 |
Why?
|
Immunohistochemistry | 4 | 2017 | 11366 | 0.130 |
Why?
|
Neurons, Afferent | 1 | 2007 | 506 | 0.130 |
Why?
|
Mohs Surgery | 1 | 2017 | 197 | 0.120 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1641 | 0.120 |
Why?
|
Receptors, Purinergic P2 | 1 | 2005 | 153 | 0.120 |
Why?
|
Antifungal Agents | 2 | 2019 | 730 | 0.120 |
Why?
|
Hyperalgesia | 1 | 2008 | 502 | 0.120 |
Why?
|
Photography | 1 | 2017 | 520 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2014 | 2043 | 0.110 |
Why?
|
Interferons | 1 | 2017 | 706 | 0.110 |
Why?
|
Prognosis | 4 | 2023 | 29063 | 0.110 |
Why?
|
Urothelium | 1 | 2005 | 277 | 0.110 |
Why?
|
Physostigmine | 1 | 2002 | 53 | 0.110 |
Why?
|
Estrous Cycle | 1 | 2002 | 73 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 4 | 2023 | 35421 | 0.110 |
Why?
|
Leg | 1 | 2018 | 1116 | 0.110 |
Why?
|
Administration, Topical | 2 | 2014 | 690 | 0.110 |
Why?
|
Boston | 2 | 2023 | 9313 | 0.110 |
Why?
|
Patient Care Planning | 1 | 2018 | 921 | 0.110 |
Why?
|
Laminin | 1 | 2014 | 419 | 0.100 |
Why?
|
Pemphigoid, Bullous | 1 | 2014 | 109 | 0.100 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2013 | 215 | 0.100 |
Why?
|
Mycophenolic Acid | 1 | 2014 | 343 | 0.100 |
Why?
|
Documentation | 1 | 2018 | 871 | 0.100 |
Why?
|
Lower Extremity | 2 | 2017 | 1158 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 2649 | 0.100 |
Why?
|
Neoplasm Invasiveness | 2 | 2017 | 3616 | 0.100 |
Why?
|
Cholinesterase Inhibitors | 1 | 2002 | 238 | 0.100 |
Why?
|
Caregivers | 1 | 2022 | 2094 | 0.090 |
Why?
|
Alopecia | 2 | 2018 | 382 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3479 | 0.090 |
Why?
|
Rheumatoid Nodule | 1 | 2010 | 15 | 0.090 |
Why?
|
Measles | 1 | 2012 | 168 | 0.090 |
Why?
|
Necrobiosis Lipoidica | 1 | 2010 | 12 | 0.090 |
Why?
|
Xanthomatosis | 1 | 2010 | 32 | 0.090 |
Why?
|
Risk Factors | 8 | 2023 | 72290 | 0.090 |
Why?
|
Mutation | 1 | 2014 | 29786 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2759 | 0.090 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2012 | 595 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20129 | 0.090 |
Why?
|
Pituitary-Adrenal System | 1 | 2002 | 553 | 0.090 |
Why?
|
Age Factors | 4 | 2020 | 18370 | 0.090 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 652 | 0.090 |
Why?
|
Monitoring, Physiologic | 1 | 2017 | 1738 | 0.080 |
Why?
|
Patient Compliance | 1 | 2019 | 2684 | 0.080 |
Why?
|
Cell Membrane | 2 | 2007 | 3748 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1061 | 0.080 |
Why?
|
Curriculum | 1 | 2022 | 3605 | 0.080 |
Why?
|
Survivors | 1 | 2019 | 2291 | 0.080 |
Why?
|
Adenosine Triphosphate | 1 | 2005 | 2025 | 0.080 |
Why?
|
Patient Care Team | 2 | 2019 | 2531 | 0.080 |
Why?
|
Lichen Planus | 1 | 2009 | 57 | 0.080 |
Why?
|
Referral and Consultation | 3 | 2021 | 3528 | 0.080 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2002 | 703 | 0.080 |
Why?
|
Sjogren's Syndrome | 1 | 2010 | 233 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2019 | 9239 | 0.080 |
Why?
|
Reference Standards | 1 | 2012 | 1025 | 0.080 |
Why?
|
Lung Neoplasms | 1 | 2013 | 13102 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2013 | 1850 | 0.080 |
Why?
|
Dermatitis | 1 | 2010 | 197 | 0.080 |
Why?
|
Postoperative Complications | 1 | 2010 | 15295 | 0.080 |
Why?
|
Interleukins | 1 | 2012 | 791 | 0.080 |
Why?
|
Health Behavior | 1 | 2019 | 2636 | 0.080 |
Why?
|
Eosinophils | 1 | 2012 | 955 | 0.070 |
Why?
|
Massachusetts | 1 | 2020 | 8663 | 0.070 |
Why?
|
Physicians | 2 | 2023 | 4567 | 0.070 |
Why?
|
Paraproteinemias | 1 | 2010 | 246 | 0.070 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1101 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8642 | 0.070 |
Why?
|
Biological Specimen Banks | 1 | 2012 | 711 | 0.070 |
Why?
|
Lipomatosis | 1 | 2007 | 112 | 0.070 |
Why?
|
Appointments and Schedules | 2 | 2020 | 417 | 0.070 |
Why?
|
Survival Rate | 2 | 2018 | 12788 | 0.070 |
Why?
|
Intestine, Small | 1 | 2012 | 1241 | 0.070 |
Why?
|
Hair | 1 | 2009 | 483 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1434 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4186 | 0.070 |
Why?
|
Autoantibodies | 1 | 2014 | 2035 | 0.060 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 4149 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2017 | 11031 | 0.060 |
Why?
|
Genetic Testing | 1 | 2018 | 3444 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2012 | 1257 | 0.060 |
Why?
|
Cohort Studies | 3 | 2018 | 40561 | 0.060 |
Why?
|
Sarcoidosis | 1 | 2010 | 506 | 0.060 |
Why?
|
Cross-Sectional Studies | 6 | 2022 | 25043 | 0.060 |
Why?
|
Incidence | 2 | 2020 | 20947 | 0.060 |
Why?
|
Bone Marrow Transplantation | 1 | 2012 | 2765 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 3923 | 0.060 |
Why?
|
Immunotherapy | 1 | 2019 | 4445 | 0.060 |
Why?
|
Early Detection of Cancer | 3 | 2022 | 3086 | 0.060 |
Why?
|
Methotrexate | 1 | 2010 | 1727 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2019 | 10481 | 0.060 |
Why?
|
Risk Assessment | 3 | 2023 | 23338 | 0.050 |
Why?
|
Hypertrichosis | 1 | 2021 | 25 | 0.050 |
Why?
|
Staphylococcus aureus | 1 | 2010 | 1451 | 0.050 |
Why?
|
Skin Care | 1 | 2021 | 49 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39050 | 0.050 |
Why?
|
Hair Removal | 1 | 2021 | 42 | 0.050 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13695 | 0.050 |
Why?
|
Antirheumatic Agents | 1 | 2010 | 1339 | 0.040 |
Why?
|
Electronics | 1 | 2021 | 322 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 2957 | 0.040 |
Why?
|
Rabbits | 2 | 2007 | 4894 | 0.040 |
Why?
|
Stem Cells | 1 | 2012 | 3567 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1873 | 0.040 |
Why?
|
Cytoplasmic Vesicles | 1 | 2008 | 74 | 0.040 |
Why?
|
Pruritus | 1 | 2021 | 361 | 0.040 |
Why?
|
Primary Health Care | 3 | 2020 | 4558 | 0.040 |
Why?
|
Emollients | 1 | 2018 | 34 | 0.040 |
Why?
|
Reflex, Abnormal | 1 | 2008 | 84 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2022 | 2085 | 0.040 |
Why?
|
Cystitis | 1 | 2008 | 93 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 5172 | 0.040 |
Why?
|
Baths | 1 | 2018 | 54 | 0.040 |
Why?
|
Middle Aged | 6 | 2018 | 213383 | 0.040 |
Why?
|
Nail Diseases | 1 | 2018 | 51 | 0.040 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2010 | 2104 | 0.040 |
Why?
|
Cell Shape | 1 | 2008 | 375 | 0.040 |
Why?
|
Vitiligo | 1 | 2018 | 89 | 0.040 |
Why?
|
Neutrophils | 1 | 2010 | 3719 | 0.040 |
Why?
|
Iatrogenic Disease | 1 | 2020 | 547 | 0.040 |
Why?
|
Transforming Growth Factor alpha | 1 | 2007 | 135 | 0.040 |
Why?
|
Quality of Life | 1 | 2018 | 12804 | 0.040 |
Why?
|
Crohn Disease | 1 | 2010 | 2303 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8428 | 0.040 |
Why?
|
Phenotype | 1 | 2014 | 16365 | 0.040 |
Why?
|
Cycloheximide | 1 | 2007 | 347 | 0.040 |
Why?
|
Mutant Proteins | 1 | 2008 | 500 | 0.040 |
Why?
|
Nurse Practitioners | 1 | 2019 | 270 | 0.040 |
Why?
|
Capital Financing | 1 | 2016 | 58 | 0.030 |
Why?
|
Disease Management | 2 | 2018 | 2459 | 0.030 |
Why?
|
Mice, Knockout | 3 | 2012 | 14557 | 0.030 |
Why?
|
Patients | 1 | 2023 | 900 | 0.030 |
Why?
|
Electric Capacitance | 1 | 2005 | 14 | 0.030 |
Why?
|
Receptors, Purinergic P2X3 | 1 | 2005 | 9 | 0.030 |
Why?
|
Receptors, Purinergic P2X2 | 1 | 2005 | 9 | 0.030 |
Why?
|
Purinergic P2 Receptor Agonists | 1 | 2005 | 14 | 0.030 |
Why?
|
Waiting Lists | 1 | 2020 | 692 | 0.030 |
Why?
|
United States | 5 | 2022 | 69872 | 0.030 |
Why?
|
Receptor, erbB-2 | 2 | 2014 | 2416 | 0.030 |
Why?
|
Office Visits | 1 | 2020 | 598 | 0.030 |
Why?
|
Physical Examination | 1 | 2021 | 1237 | 0.030 |
Why?
|
Pyridoxal Phosphate | 1 | 2005 | 127 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2008 | 913 | 0.030 |
Why?
|
Brain | 1 | 2022 | 26385 | 0.030 |
Why?
|
Benzoyl Peroxide | 1 | 2014 | 18 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2019 | 63114 | 0.030 |
Why?
|
Clindamycin | 1 | 2014 | 139 | 0.030 |
Why?
|
Research | 1 | 2023 | 1999 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 2007 | 708 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2012 | 19905 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 2 | 2007 | 8301 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2014 | 57776 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1486 | 0.030 |
Why?
|
Needs Assessment | 1 | 2019 | 1147 | 0.030 |
Why?
|
Aftercare | 1 | 2019 | 866 | 0.030 |
Why?
|
Minocycline | 1 | 2014 | 163 | 0.030 |
Why?
|
Mice | 5 | 2022 | 81183 | 0.030 |
Why?
|
Time Factors | 2 | 2018 | 40075 | 0.030 |
Why?
|
Mucous Membrane | 1 | 2007 | 673 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2008 | 683 | 0.030 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 491 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2012 | 21827 | 0.030 |
Why?
|
Apyrase | 1 | 2005 | 364 | 0.030 |
Why?
|
Arginine Vasopressin | 1 | 2002 | 130 | 0.030 |
Why?
|
Sensory Receptor Cells | 1 | 2007 | 492 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2022 | 2455 | 0.030 |
Why?
|
Sampling Studies | 1 | 2014 | 623 | 0.030 |
Why?
|
Epithelium | 1 | 2007 | 1679 | 0.030 |
Why?
|
Tyrosine | 1 | 2007 | 1461 | 0.030 |
Why?
|
Oximes | 1 | 2014 | 311 | 0.030 |
Why?
|
Motivation | 1 | 2022 | 1971 | 0.030 |
Why?
|
Radiotherapy | 1 | 2019 | 1533 | 0.030 |
Why?
|
Corticosterone | 1 | 2002 | 310 | 0.030 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2013 | 298 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2007 | 1285 | 0.030 |
Why?
|
Administration, Cutaneous | 1 | 2014 | 711 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2014 | 371 | 0.030 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 1411 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2013 | 898 | 0.020 |
Why?
|
Mycoses | 1 | 2014 | 376 | 0.020 |
Why?
|
Receptors, Interleukin | 1 | 2012 | 245 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2010 | 5751 | 0.020 |
Why?
|
Interleukin-23 | 1 | 2012 | 193 | 0.020 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2013 | 252 | 0.020 |
Why?
|
Endocytosis | 1 | 2005 | 985 | 0.020 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2002 | 648 | 0.020 |
Why?
|
Wound Healing | 1 | 2021 | 2785 | 0.020 |
Why?
|
Animals | 6 | 2022 | 168757 | 0.020 |
Why?
|
Public Health | 1 | 2023 | 2603 | 0.020 |
Why?
|
Psoriasis | 1 | 2018 | 898 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2002 | 511 | 0.020 |
Why?
|
Melanocytes | 1 | 2013 | 515 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 1676 | 0.020 |
Why?
|
Autoantigens | 1 | 2014 | 892 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2014 | 847 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4554 | 0.020 |
Why?
|
Pyridones | 1 | 2014 | 712 | 0.020 |
Why?
|
Signal Transduction | 3 | 2007 | 23403 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2278 | 0.020 |
Why?
|
Glycoproteins | 1 | 2007 | 2263 | 0.020 |
Why?
|
Gene Amplification | 1 | 2013 | 1063 | 0.020 |
Why?
|
Drug Combinations | 1 | 2014 | 1959 | 0.020 |
Why?
|
Rats | 2 | 2007 | 24260 | 0.020 |
Why?
|
Pain Measurement | 1 | 2008 | 3420 | 0.020 |
Why?
|
Causality | 1 | 2014 | 1275 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 17446 | 0.020 |
Why?
|
Imidazoles | 1 | 2014 | 1206 | 0.020 |
Why?
|
Aged | 3 | 2018 | 163280 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2014 | 20822 | 0.020 |
Why?
|
Health Care Reform | 1 | 2016 | 1261 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 3022 | 0.020 |
Why?
|
Cystic Fibrosis | 1 | 2014 | 1177 | 0.020 |
Why?
|
Phosphorylation | 1 | 2007 | 8436 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2007 | 3690 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5391 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2012 | 6386 | 0.010 |
Why?
|
Pediatrics | 1 | 2018 | 3475 | 0.010 |
Why?
|
Health Personnel | 1 | 2016 | 3218 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2942 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3749 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2014 | 2727 | 0.010 |
Why?
|
Calcium | 1 | 2005 | 5756 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2012 | 5974 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2021 | 25625 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 21746 | 0.010 |
Why?
|
Neoplasms | 1 | 2010 | 21683 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15540 | 0.010 |
Why?
|
Comorbidity | 1 | 2014 | 10388 | 0.010 |
Why?
|
Sex Factors | 1 | 2002 | 10397 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5319 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13284 | 0.010 |
Why?
|
Apoptosis | 1 | 2013 | 9727 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 16689 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18029 | 0.010 |
Why?
|
HIV Infections | 1 | 2007 | 16718 | 0.000 |
Why?
|